english.prescrire.org > Spotlight > Archives : 2014 > In the July issue of Prescrire International: Canakinumab for gout attacks

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2014 : 1 | 30 | 60

In the July issue of Prescrire International: Canakinumab for gout attacks

FREE DOWNLOAD Given its uncertain efficacy on gout-related pain, canakinumab is too risky to use for treatment of gout attacks. Its price is also exorbitant. It is better to stick with existing symptomatic treatments, which should be initiated as early as possible.
Full text available for free download.

Summary

  • There are no clinical trials of canakinumab in patients with gout attacks refractory to several prior treatments.
     
  • Adverse effects mainly include infections, hypersensitivity reactions and dizziness.

Full text available for free download.

 ©Prescrire 1 July 2014

"Canakinumab for gout attacks. Too risky" Prescrire Int 2014; 23 (151): 178. (Pdf, free).
Download the full review
Pdf, free